RxDoctor Payments Data

Hassan Saradih, MD

Internal Medicine · Lenexa, KSNPI 1538252622

Payments from drug & device makers

$1,121in general payments, 2019–2025

Across 36 payments — averaging $31.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$352
  • Tris Pharma Inc$287
  • Sunovion Pharmaceuticals Inc.$156
  • Acadia Pharmaceuticals Inc$117
  • Lilly USA, LLC$60
  • Takeda Pharmaceuticals U.S.A., Inc.$31
  • plus $118 from 6 others

What the payments were for

  • Food & beverage$1,121100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,121 in reported general payments places this provider in the 75th percentile of 705 internal medicine providers in Kansas.

See all internal medicine providers in Kansas

Medicare billing

Part B allowed, 2024
$278,936
Medicare patients
342
Services billed
3,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide51$53,393
OzempicSemaglutide37$47,714
EliquisApixaban47$33,731
VyvanseLisdexamfetamine Dimesylate32$12,164
XareltoRivaroxaban11$7,962
JardianceEmpagliflozin11$6,583
Humalog Kwikpen U-100Insulin Lispro11$1,767
Gabapentin97$1,652
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,270
Zolpidem Tartrate ErZolpidem Tartrate21$924
Ondansetron OdtOndansetron32$745
Trazodone Hcl83$679
Albuterol Sulfate HfaAlbuterol Sulfate26$654
Cyclobenzaprine Hcl63$637
Atorvastatin Calcium96$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$60$53,39351 claims
Novo NordiskOzempic$352$47,71437 claims
PfizerEliquis$15$33,73147 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$31$12,16432 claims
Johnson & JohnsonXarelto$22$7,96211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 705 internal medicine providers in Kansas.

Other internal medicine in Lenexa

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →